Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice

Drug Metabolism and Disposition

Volumn 31, Issue 4, 2003, Pages 491-501

  Zhang, Ji Y ^a,b   Yuan, Josh J ^a   Wang, Yue Fen ^a   Bible Jr , Roy H ^a   Breau, Alan P ^a  

^a Global Drug Metabolism   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; VALDECOXIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GLUCURONIDATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RECEPTOR AFFINITY;

ANIMALS; BIOTRANSFORMATION; CARBON ISOTOPES; CARBON RADIOISOTOPES; CHROMATOGRAPHY, LIQUID; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLUCURONIDASE; HYDROLYSIS; ISOENZYMES; ISOXAZOLES; MAGNETIC RESONANCE IMAGING; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED STRAINS; PLASMA; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONAMIDES; TIME FACTORS;

ANIMALIA;

EID: 0037378676     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.4.491     Document Type: Article

References (19)

1. Camu F, Beecher T, Recker DP, and Verburg KM (2002) Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. Am J Ther 9:43-51.
2. Dekant W, Vamvakas S, and Anders MW (1994) Formation and fate of nephrotoxic and cytotoxic glutathione S-conjugates: cysteine conjugate beta-lyase pathway. Adv Pharmacol 27:115-162.
3. Donnelly MT and Hawkey CJ (1997) COX-2 inhibitors - a new generation of safer NSAIDs? Aliment Pharmacol Ther 11:227-236.
4. Elder DJE and Paraskeva C (1998) COX-2 inhibitors for colorectal cancer. Nat Med 4:392-393.
5. Fricke J, Varkalis J, Zwillich S, Adler R, Forester E, Recker DP, and Verburg KM (2002) Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. Am J Ther 9:89-97.
6. Hecker J (1998) Alzheimer's disease: the advent of effective therapy. Aust NZ J Med 28:765-771.
7. Isakson PC, Zweifel BS, Masferrer JL, Koboldt C, Seibert K, Hubbard RC, Geis GS, and Needleman P (1998) Specific COX-2 inhibitors: from bench to bedside, in Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential (Vane J and Botting J eds) pp 127-133. Kluwer Academic Publishers and William Harvey Press, London, UK.
8. Karim A and Brown EA (1972) Isolation and identification of novel sulfur-containing metabolites of spironolactone (Aldactone). Steroids 20:41-62.
9. Karim A, Hribar J, Aksamit W, Doherty M, and Chinn LJ (1975) Spironolactone metabolism in man studied by gas chromatography-mass spectrometry. Drug Metab Dispos 3:467-478.
10. Paulson SK, Zhang JY, Breau AP, Hribar JD, Liu NW, Jessen SM, Lawal YM, Cogburn JN, Gresk CJ, Markos CS, et al. (2000) Pharmacokinetics, tissue distribution, metabolism and excretion of celecoxib in rats. Drug Metab Dispos 28:514-521.
11. Paulson SK, Zhang JY, Jessen SM, Lawal Y, Liu NW, Dudkowski CM, Wang YF, Chang M, Yang D, Findlay JW, et al. (2000) Comparison of celecoxib metabolism and excretion in mouse, rabbit, dog, cynomolgus monkey and rhesus monkey. Xenobiotica 30:731-744.
12. Pennisi E (1998) Building better aspirin and does aspirin ward off cancer and Alzheimer's, Science (Wash DC) 280:1191-1192.
13. Prakash C, Kamel A, Gumerus J, and Wilner K (1997) Metabolism and excretion of the antipsychotic drug ziprasidone. Drug Metab Dispos 25:863-872.
14. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, Isakson PC, and Geis GS (1998) Preliminary study of the safety and efficacy of SC-58635, a novel cycolooxygenase 2 inhibitor. Arthritis Rheum 41:1591-1602.
15. Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Perkins WE, Rogers RS, Shaffer AF, Zhang YY, et al. (2000) 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem 43:775-777.
16. Vane JR, Bakhle YS, and Botting RM (1998) Cyclooxygense 1 and 2. Annu Rev Pharmacol Toxicol 38:97-120.
17. Yuan JJ, Yang D, Zhang JY, Bible B, Karim A, and Findlay JAW (2002) Disposition of a specific COX-2 inhibitor, valdecoxib, in humans. Drug Metab Dispos 30:1013-1021.
18. Zhang JY, Wang YF, Dudkowski C, Yang D, Chang M, Yuan J, Paulson SK, and Breau AP (2000) Characterization of metabolites of celecoxib in rabbits by liquid chromatography/ tandem mass spectrometry. J Mass Spectrom 35:1259-1270.
19. Ziegler J (1998) Cancer and arthritis share underlying processes. J Natl Cancer Inst 90:802-803.